What is the recommended treatment for peripheral arterial occlusive disease (PAD)?

Treatment of Peripheral Arterial Occlusive Disease (PAOD)

All patients with symptomatic PAOD should receive aspirin (75-325 mg daily) or clopidogrel (75 mg daily) plus a high-intensity statin, combined with supervised exercise training (30-45 minutes, 3 times weekly for minimum 12 weeks), and cilostazol (100 mg twice daily) should be added for lifestyle-limiting claudication if no heart failure is present. 1, 2

Medical Therapy Framework

Antiplatelet Therapy (Class I - Strongest Evidence)

For symptomatic PAD:

• Aspirin 75-325 mg daily OR Clopidogrel 75 mg daily as monotherapy 1, 2, 3
• Clopidogrel is preferred based on CAPRIE trial data showing superior outcomes 2
• Do NOT use warfarin - it provides no benefit and increases major bleeding risk 1

For asymptomatic PAD (ABI ≤0.90):

• Antiplatelet therapy is reasonable but less strongly recommended (Class IIa) 1, 2

Dual antiplatelet therapy considerations:

• Rivaroxaban 2.5 mg twice daily + aspirin 100 mg daily should be considered for high ischemic risk patients with non-high bleeding risk 4
• This combination reduces cardiovascular death, MI, and stroke compared to aspirin alone 5
• Standard dual antiplatelet (aspirin + clopidogrel) is NOT well-established for routine use but may be reasonable post-revascularization 1, 2

Statin Therapy (Class I)

• High-intensity statin for ALL patients with PAD regardless of symptoms 2
• This reduces cardiovascular events and mortality 1

Antihypertensive Therapy (Class I)

• Treat hypertension to reduce MI, stroke, heart failure, and cardiovascular death 2
• ACE inhibitors or ARBs are particularly effective for reducing cardiovascular events in PAD 2

Risk Factor Modification (Class I)

Smoking cessation (mandatory):

• Counsel at every visit 1
• Offer pharmacotherapy: varenicline, bupropion, or nicotine replacement 1

Diabetes management:

• Optimize glycemic control to reduce microvascular complications 1

Exercise Therapy (Class I - Strongest Evidence)

Supervised exercise training is the cornerstone of initial treatment for intermittent claudication 1, 2:

• Minimum 30-45 minutes per session
• At least 3 times per week
• Minimum 12 weeks duration
• Exercise to moderate-severe claudication pain for best results 4
• Unsupervised programs are NOT well-established as effective (Class IIb) 1

Pharmacotherapy for Claudication Symptoms

Cilostazol (Class I - First-Line)

• 100 mg orally twice daily 1
• Indicated for ALL patients with lifestyle-limiting claudication (contraindicated in heart failure) 1
• Improves symptoms and increases walking distance with Level A evidence 1
• Side effects: headache, diarrhea, dizziness, palpitations (20% discontinuation rate) 2

Pentoxifylline (Class IIb - Second-Line)

• 400 mg three times daily 1
• Only as alternative to cilostazol
• Clinical effectiveness is marginal and not well-established 1

Avoid These Therapies:

• Chelation therapy (Class III: Harm) - may have harmful adverse effects 1
• L-arginine, propionyl-L-carnitine, ginkgo biloba - effectiveness not well-established 1

Revascularization Decision Algorithm

When to Consider Revascularization for Claudication:

Prerequisites (all must be met):

1. Symptoms are functionally/lifestyle-limiting
2. Inadequate response to 3 months of guideline-directed medical therapy + supervised exercise 4, 6
3. Risk-benefit assessment favors intervention
4. Hemodynamically significant lesions present

Revascularization is NOT recommended for:

• Asymptomatic PAD (Class III: No benefit) 4, 6
• Solely to prevent progression to CLTI 4

Endovascular vs. Surgical Approach

Endovascular-first strategy (Class I):

• Preferred for TASC A and B lesions 1
• Indicated for aortoiliac or femoropopliteal disease with favorable anatomy 1
• Iliac artery lesions: Stenting is effective as primary therapy for common and external iliac stenosis/occlusions 1
• Covered balloon-expandable stents show superior patency (74.7% at 5 years vs 62.5% for bare metal) 5
• Drug-eluting treatment should be considered first-choice for femoropopliteal lesions 4

Surgical revascularization (Class IIa/IIb):

• Reasonable when:
  • Preoperative risk is acceptable
  • Technical factors favor surgery over endovascular
  • Autologous saphenous vein available 4, 6
• Consider for TASC C and D lesions, though recent data support endovascular-first even for these 5

Avoid:

• Primary stenting in femoral, popliteal, or tibial arteries (Class III) 1
• Intervention without significant pressure gradient despite vasodilation 1

Chronic Limb-Threatening Ischemia (CLTI)

Immediate actions:

• Early recognition and urgent vascular team referral (Class I) 4
• Revascularization as soon as possible 4
• Eliminate inflow obstructions when treating downstream lesions 4

Medical management:

• Continue all cardiovascular risk reduction therapies
• Offload mechanical stress for ulcer healing 4
• Do NOT use exercise training in patients with wounds 4

Revascularization approach:

• Autologous veins preferred for infra-inguinal bypass 4
• Endovascular may be considered first-line, especially in high surgical risk patients 4
• For patients with good veins and low surgical risk, infra-inguinal bypass may be considered 4

Common Pitfalls to Avoid

1. Using cilostazol as substitute for antiplatelet therapy - cilostazol treats symptoms only; antiplatelet therapy prevents cardiovascular events 7
2. Adding warfarin to antiplatelet therapy - increases bleeding without benefit 1
3. Revascularizing asymptomatic PAD - increases MALE risk without proven benefit 6
4. Skipping supervised exercise trial - revascularization should follow inadequate response to 3-month trial 4, 6
5. Using unsupervised exercise programs - effectiveness not established 1

Follow-Up Protocol

• Assess at least annually: clinical status, functional status, medication adherence, limb symptoms, cardiovascular risk factors 4
• Use duplex ultrasound as needed 4
• Medication reconciliation at each visit to ensure guideline-directed therapy is maintained 7